PT3009426T - Derivado de 4-alquinilimidazole e medicamento compreendendo o mesmo como ingrediente ativo - Google Patents
Derivado de 4-alquinilimidazole e medicamento compreendendo o mesmo como ingrediente ativoInfo
- Publication number
- PT3009426T PT3009426T PT148111545T PT14811154T PT3009426T PT 3009426 T PT3009426 T PT 3009426T PT 148111545 T PT148111545 T PT 148111545T PT 14811154 T PT14811154 T PT 14811154T PT 3009426 T PT3009426 T PT 3009426T
- Authority
- PT
- Portugal
- Prior art keywords
- medicine
- same
- active ingredient
- imidazole derivative
- alkynyl
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013123968 | 2013-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3009426T true PT3009426T (pt) | 2018-06-08 |
Family
ID=52022361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT148111545T PT3009426T (pt) | 2013-06-12 | 2014-06-12 | Derivado de 4-alquinilimidazole e medicamento compreendendo o mesmo como ingrediente ativo |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9593081B2 (show.php) |
| EP (1) | EP3009426B1 (show.php) |
| JP (1) | JP6276760B2 (show.php) |
| KR (1) | KR102212981B1 (show.php) |
| CN (1) | CN105431416B (show.php) |
| AU (1) | AU2014279113B2 (show.php) |
| BR (1) | BR112015030315B1 (show.php) |
| CA (1) | CA2914997C (show.php) |
| DK (1) | DK3009426T3 (show.php) |
| ES (1) | ES2669977T3 (show.php) |
| HR (1) | HRP20180703T1 (show.php) |
| HU (1) | HUE039015T2 (show.php) |
| IL (1) | IL242912A0 (show.php) |
| LT (1) | LT3009426T (show.php) |
| MX (1) | MX369804B (show.php) |
| MY (1) | MY168609A (show.php) |
| NO (1) | NO3009426T3 (show.php) |
| NZ (1) | NZ715837A (show.php) |
| PH (1) | PH12015502745B1 (show.php) |
| PL (1) | PL3009426T3 (show.php) |
| PT (1) | PT3009426T (show.php) |
| RS (1) | RS57406B1 (show.php) |
| RU (1) | RU2662806C2 (show.php) |
| SG (1) | SG11201510121RA (show.php) |
| SI (1) | SI3009426T1 (show.php) |
| TR (1) | TR201807659T4 (show.php) |
| WO (1) | WO2014200075A1 (show.php) |
| ZA (1) | ZA201600135B (show.php) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO3009426T3 (show.php) * | 2013-06-12 | 2018-09-29 | ||
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| US20190276429A1 (en) * | 2016-11-18 | 2019-09-12 | Dow Agrosciencesllc | 4-(6-(2-(2,4-difluorophenyl)-1.1-difluoro-2-hydroxy-3-(5-mercapto-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation |
| AR111806A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| HUE056382T2 (hu) | 2017-05-18 | 2022-02-28 | Idorsia Pharmaceuticals Ltd | Pirimidin-származékok mint PGE2 receptor modulátorok |
| JP7253500B2 (ja) | 2017-05-18 | 2023-04-06 | イドーシア ファーマシューティカルズ リミテッド | ピリミジン誘導体 |
| AU2018269666B2 (en) | 2017-05-18 | 2022-02-03 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as PGE2 receptor modulators |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| WO2018216640A1 (ja) * | 2017-05-22 | 2018-11-29 | 小野薬品工業株式会社 | Ｅｐ４アンタゴニスト |
| JP2020142989A (ja) * | 2017-06-21 | 2020-09-10 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | イミダゾール誘導体及びそれを含有する医薬 |
| EP3749323A4 (en) * | 2018-02-05 | 2021-11-03 | Shenzhen Ionova Life Science Co., Ltd. | HETEROBICYCLIC CARBONIC ACIDS FOR TREATMENT OF CANCER OR INFLAMMATORY DISEASES |
| CN108997252B (zh) * | 2018-07-27 | 2020-04-28 | 常州大学 | 一种恶二唑衍生物的绿色合成方法 |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2436551A1 (en) | 2001-01-31 | 2002-08-08 | Pfizer Products Inc. | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
| NZ531153A (en) * | 2001-08-09 | 2005-10-28 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| CN1662551A (zh) | 2002-05-23 | 2005-08-31 | 瑟瑞技术公司 | 前列腺素e2受体亚型ep4的拮抗肽 |
| BRPI0414130B8 (pt) | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
| CA2565813C (en) | 2004-05-04 | 2010-10-26 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| JP4054369B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | オルト置換アリールまたはヘテロアリールアミド化合物 |
| BRPI0607439A2 (pt) * | 2005-02-16 | 2010-04-06 | Solvay Pharm Bv | compostos, composição farmacêutica, método de preparação de composições farmacêuticas, e, uso de um composto |
| CA2648729A1 (en) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Indole amide derivatives as ep4 receptor antagonists |
| US7705035B2 (en) | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
| AU2007283404B2 (en) | 2006-08-11 | 2013-04-18 | Merck Canada Inc. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
| CN101622230B (zh) * | 2007-02-26 | 2012-08-22 | 默克弗罗斯特加拿大有限公司 | 作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物 |
| RU2010103104A (ru) * | 2007-07-02 | 2011-08-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные имидазола в качестве антагонистов рецептора ccr2 |
| WO2009005076A1 (ja) | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
| JP5375824B2 (ja) | 2008-05-14 | 2013-12-25 | アステラス製薬株式会社 | アミド化合物 |
| CN102149384B (zh) | 2008-08-14 | 2014-08-20 | 南京奥昭生物科技有限公司 | 作为ep4受体拮抗剂的杂环酰胺衍生物 |
| SI2619182T1 (sl) * | 2010-09-21 | 2017-03-31 | Eisai R&D Management Co., Ltd. | Farmacevtski sestavek |
| US8828987B2 (en) | 2010-12-10 | 2014-09-09 | Rottapharm Biotech S.R.L. | Pyridine amide derivatives as EP4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| CA2839116C (en) | 2011-07-04 | 2019-07-16 | Rottapharm S.P.A. | Cyclic amine derivatives as ep4 receptor antagonists |
| NO3009426T3 (show.php) * | 2013-06-12 | 2018-09-29 |
-
2014
- 2014-06-12 NO NO14811154A patent/NO3009426T3/no unknown
- 2014-06-12 LT LTEP14811154.5T patent/LT3009426T/lt unknown
- 2014-06-12 RS RS20180743A patent/RS57406B1/sr unknown
- 2014-06-12 NZ NZ715837A patent/NZ715837A/en unknown
- 2014-06-12 WO PCT/JP2014/065643 patent/WO2014200075A1/ja not_active Ceased
- 2014-06-12 US US14/897,324 patent/US9593081B2/en active Active
- 2014-06-12 EP EP14811154.5A patent/EP3009426B1/en active Active
- 2014-06-12 CA CA2914997A patent/CA2914997C/en active Active
- 2014-06-12 SI SI201430707T patent/SI3009426T1/en unknown
- 2014-06-12 HU HUE14811154A patent/HUE039015T2/hu unknown
- 2014-06-12 AU AU2014279113A patent/AU2014279113B2/en active Active
- 2014-06-12 HR HRP20180703TT patent/HRP20180703T1/hr unknown
- 2014-06-12 ES ES14811154.5T patent/ES2669977T3/es active Active
- 2014-06-12 BR BR112015030315-3A patent/BR112015030315B1/pt active IP Right Grant
- 2014-06-12 CN CN201480044505.6A patent/CN105431416B/zh active Active
- 2014-06-12 RU RU2015155585A patent/RU2662806C2/ru active
- 2014-06-12 TR TR2018/07659T patent/TR201807659T4/tr unknown
- 2014-06-12 MY MYPI2015704535A patent/MY168609A/en unknown
- 2014-06-12 KR KR1020167000476A patent/KR102212981B1/ko active Active
- 2014-06-12 PL PL14811154T patent/PL3009426T3/pl unknown
- 2014-06-12 JP JP2015522867A patent/JP6276760B2/ja active Active
- 2014-06-12 DK DK14811154.5T patent/DK3009426T3/en active
- 2014-06-12 SG SG11201510121RA patent/SG11201510121RA/en unknown
- 2014-06-12 PT PT148111545T patent/PT3009426T/pt unknown
- 2014-06-12 MX MX2015017161A patent/MX369804B/es active IP Right Grant
-
2015
- 2015-12-03 IL IL242912A patent/IL242912A0/en active IP Right Grant
- 2015-12-09 PH PH12015502745A patent/PH12015502745B1/en unknown
-
2016
- 2016-01-07 ZA ZA2016/00135A patent/ZA201600135B/en unknown
-
2017
- 2017-01-24 US US15/414,200 patent/US9855257B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201600135B (en) | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | |
| IL263978B (en) | Amorphous latrovir and solid pharmaceutical preparations containing it and its uses | |
| IL243042A0 (en) | Consequences of aminotriazine and a pharmaceutical preparation containing it | |
| IL240849A0 (en) | Drug delivery devices and drug delivery method | |
| IL238713A0 (en) | Self-regulating active pharmaceutical ingredient release | |
| SMT202500203T1 (it) | Dispositivi di erogazione di farmaco con componente permeabile al farmaco | |
| ZA201508118B (en) | Herbicidally active (alkynyl-phenyl)-substituted cyclic dione compounds and derivatives thereof | |
| ZA201603272B (en) | Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin | |
| ZA201405949B (en) | Pharmaceutical preparation containing and antivirally active dihydroquinazoline derivative | |
| PL2998296T3 (pl) | Pochodna kwasu cykloalkilowego, sposób jej otrzymywania i jej zastosowanie farmaceutyczne | |
| EP3050875A4 (en) | Novel imidazole derivative and therapeutical use thereof | |
| SG11201505640VA (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
| ZA201504520B (en) | Active ingredient microparticles | |
| ZA201507576B (en) | Pharmaceutical combination drug | |
| SG11201509194SA (en) | Radiomitigating pharmaceutical formulations | |
| IL243223B (en) | History of imidazole, their preparation and pharmaceutical preparations containing them | |
| ZA201601645B (en) | Bendamustine pharmaceutical compositions | |
| GB201316023D0 (en) | Continuous low dosing of an active ingredient | |
| IL245983A0 (en) | Biologically active insulin derivatives | |
| PL3043791T3 (pl) | Środek przeciwnowotworowy zawierający związek aminoacetonitrylowy jako substancję czynną | |
| IL244316A0 (en) | A new composition of a drug | |
| GB201302851D0 (en) | Ingredient Wrap | |
| ZA201405476B (en) | Anthelmintic medicament | |
| GB201316498D0 (en) | Topical Pharmaceutical formulation | |
| AU2013901834A0 (en) | Formulations and Therapeutic Uses Thereof |